Literature DB >> 23836856

Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial.

Mark E Cooper1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23836856      PMCID: PMC3761003          DOI: 10.1503/cmaj.130507

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

1.  Angiotensin-converting enzyme inhibitors: first-line agents in cardiovascular protection?

Authors:  Frank Ruschitzka; Stefano Taddei
Journal:  Eur Heart J       Date:  2012-06-01       Impact factor: 29.983

2.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

Review 3.  Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines.

Authors:  Onil K Bhattacharyya; Baiju R Shah; Gillian L Booth
Journal:  CMAJ       Date:  2008-09-18       Impact factor: 8.262

4.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

Authors:  John A Dormandy; Bernard Charbonnel; David J A Eckland; Erland Erdmann; Massimo Massi-Benedetti; Ian K Moules; Allan M Skene; Meng H Tan; Pierre J Lefèbvre; Gordon D Murray; Eberhard Standl; Robert G Wilcox; Lars Wilhelmsen; John Betteridge; Kåre Birkeland; Alain Golay; Robert J Heine; László Korányi; Markku Laakso; Marián Mokán; Antanas Norkus; Valdis Pirags; Toomas Podar; André Scheen; Werner Scherbaum; Guntram Schernthaner; Ole Schmitz; Jan Skrha; Ulf Smith; Jan Taton
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

5.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

6.  Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Authors:  Anne Katrin Sjølie; Ronald Klein; Massimo Porta; Trevor Orchard; John Fuller; Hans Henrik Parving; Rudy Bilous; Nish Chaturvedi
Journal:  Lancet       Date:  2008-09-25       Impact factor: 79.321

7.  Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

Authors:  Stephen C Benson; Harrihar A Pershadsingh; Christopher I Ho; Amar Chittiboyina; Prashant Desai; Michal Pravenec; Nianning Qi; Jiaming Wang; Mitchell A Avery; Theodore W Kurtz
Journal:  Hypertension       Date:  2004-03-08       Impact factor: 10.190

8.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

9.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

Review 10.  Management of type 2 diabetes: new and future developments in treatment.

Authors:  Abd A Tahrani; Clifford J Bailey; Stefano Del Prato; Anthony H Barnett
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

View more
  1 in total

1.  comparative effectiveness research collaboration and precision medicine.

Authors:  Price A; Chatterjee P; Biswas R
Journal:  Ann Neurosci       Date:  2015-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.